The risk for HCV reinfection among patients who reported injection drug use was increased in the initial period after curative treatment but decreased over time.
Currently, there are no specific antiviral drugs available for treating hepatitis E virus (HEV) infection, which represents a global health burden, causing acute viral hepatitis with varying clinical ...
Pharmaceutical companies are heavily investing in R&D to enhance drug efficacy, reduce treatment durations, and minimize side effects. In terms of treatment types, the hepatitis treatment market ...
Autoimmune Hepatitis Emerging Drugs VAY736: Novartis VAY736 is an antibody that targets B-cell activating factor receptor (BAFF-R), designed to block BAFF-R-mediated signaling and to deplete B-cells ...